Company Market Research Report: Crohn’s & Colitis Australia (CCA)
Company Overview
Name
Crohn’s & Colitis Australia (CCA)
(Australian Crohn’s and Colitis Association for legal purposes)
Mission
"At CCA we dream of a future that is free of Crohn’s and colitis. We empower people to live fearlessly while we help search for a cure."
Founded
Established over 35 years ago
Founders
No information is available
Key People
1. Bruce Rosengarten - Chairman
2. James Oliver - Director, Treasurer
3. Dominique Tim So - Director, Company Secretary
4. Leanne Raven FAICD - Chief Executive Officer
5. Wayne Massuger - Head – Research, Quality & Support Programs
6. Sarah Thyssen - Head – Philanthropy, Development & Engagement
7. Renee Hill - Chief Financial Officer
8. Tim Costello - Office & Membership Manager
9. Ian Stewart - Digital Manager
Headquarters
Level 1, Suite 4, 363 Camberwell Road Camberwell, VIC 3124, Australia
Number of Employees
No information is available
Revenue
No information is available
Known For
Empowering over 100,000 Australian men, women, and children living with Crohn’s disease or ulcerative colitis (collectively known as inflammatory bowel disease – IBD) to live fearlessly.
Products
Support Services
1. Helplines & NurseLine Assessments
- High-Level Description: Providing advice and support through telephone helplines and assessments.
- Key Features: 725 Helpline calls and NurseLine assessments annually.
2. Connect with a Peer
- High-Level Description: Connecting individuals with a peer for support.
- Key Features: No detailed features available.
3. Support Groups and Information Forums
- High-Level Description: Offering support groups and information forums for shared experiences and advice.
- Key Features: No detailed features available.
Research Investment
1. Research Grants & Awards
- High-Level Description: Fundraising and investing in research into IBD.
- Key Features:
- $650K in research grants
- Various scholarships such as CCA IBD Scholarship, Mandy and Edward Yencken Postgraduate Research Scholarship, Ferring IBD Clinical Project Award, etc.
Recent Developments
New Features and Products
- New treatment approved by PBAC for pouchitis: Vedolizumab expected to be added to the PBS indications for chronic pouchitis.
Recent Publications and Reports
- Strategy Toward 2026
- Purpose:
- Improve quality of life by helping people understand, respond to, and actively manage their care.
- Empower and support the community.
- Advocate, educate, and facilitate.
New Partnerships and Initiatives
- Live Fearless Challenge 2024: Fundraising initiative for people living with Crohn's and colitis.
- Health Industry Hub Awards 2024 Nomination: Contender for NGO of the year.
Conclusion
Crohn’s & Colitis Australia (CCA) continues to make significant strides in supporting those living with IBD through extensive research investments, support services, and advocacy. The organization’s strategic goals aim towards improving quality of care, driving research for cures, and fostering a supportive community. Despite the lack of detailed financial and employment data, CCA's impact and ongoing initiatives reflect its commitment to the IBD community.
